614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Targeted Therapies
Watch Session
464 Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study according to ASH clinically relevant abstract
Nicholas J. Short, Hagop M. Kantarjian, Farhad Ravandi, et al.
465 Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia according to ASH clinically relevant abstract
Nicholas J. Short, Hagop M. Kantarjian, Keyur Patel, et al
466 Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma according to ASH clinically relevant abstract
Jeffrey E. Rubnitz, Thomas B. Alexander, Theodore W. Laetsch, et al.
467 NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) – a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity according to ASH clinically relevant abstract
Line Stensig Lynggaard, Sofie Gottschalk Højfeldt, Lisbeth Moeller, et al.
468 Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC) according to ASH clinically relevant abstract
Liora M. Schultz, Christina Baggott, Snehit Prabhu, et al.
469 In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients according to ASH clinically relevant abstract
Andrej Lissat, Despina Maniotis, Michael Nosswitz, et al.